At a glance
- Thymosin beta-4 is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 608 publications mentioning it, including 5 randomized controlled trials and 212 animal-only studies.
- ClinicalTrials.gov lists 19 registered studies testing it (3 active).
- FDA's adverse event system (FAERS) holds 3 reports mentioning it; 2 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500.
- Paracrine TMSB4X signaling from oligodendrocytes promotes diffuse glioma dissemination.
- Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
- Dysregulation of circulating damage-associated molecular patterns in diabetic foot syndrome.
- Understanding the effects of ciprofloxacin on corneal epithelial cells: a study using electric cell-substrate impedance sensing (ECIS) technology.
- PEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo.
- Effects of Supplementation in Masters Athletes and Older Adults: A Narrative Review.
- Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 19
- Active
- 3
- With posted results
- 9
Conditions studied
Show 9 more studies
All 19 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 3
- Serious
- 2
- With death outcome
- 0
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.